2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.06. Real World Outcomes of Lurbinectedin as Second Line Treatment in Extensive Stage-Small Cell Lung Cancer (ES-SCLC)

P1.06. Real World Outcomes of Lurbinectedin as Second Line Treatment in Extensive Stage-Small Cell Lung Cancer (ES-SCLC)

Back to course

Pdf Summary

Researchers from the Mayo Clinic in Rochester, Minnesota, conducted a study to evaluate the real-world outcomes of using lurbinectedin as a second-line treatment in patients with extensive stage-small cell lung cancer (ES-SCLC). The study included 50 patients who received lurbinectedin between June 2020 and June 2022.<br /><br />The baseline characteristics of the patients showed that the median age at diagnosis was 67 years, with 50% of the patients being female. The median follow-up from diagnosis and initiation of treatment was 13.3 and 5 months, respectively. The majority of patients (94%) had de novo SCLC, while a small percentage (6%) had SCLC transformed from non-small cell lung cancer (NSCLC). Eighty-two percent of patients had ES-SCLC at diagnosis.<br /><br />The median number of cycles of lurbinectedin received by the patients was 3, with most receiving the standard dose of 3.2 mg/m2. Twelve patients (24%) received a dose reduction due to previous myelosuppression, fatigue, or frailty. The median chemotherapy-free interval (CTFI) among the cohort was 74 days.<br /><br />Grade 3 or higher adverse events reported included neutropenia, anemia, thrombocytopenia, and elevated ALT, each occurring in 6% of patients. Twelve percent of patients required dose reduction due to myelosuppression or fatigue. Growth factor support was given to 20% of patients.<br /><br />The study found that there were no grade 5 toxicities associated with lurbinectedin at the standard dose. The median progression-free survival (PFS) for the cohort was 2.08 months, and the median overall survival (OS) was 5.1 months.<br /><br />In conclusion, the study showed that lurbinectedin was generally well-tolerated as a second-line treatment for relapsed/refractory ES-SCLC. However, the real-world outcomes remain suboptimal, highlighting the need for improved treatment strategies for patients with SCLC.

Asset Subtitle

Aakash Desai, Mayo Clinic, United States

Meta Tag

Speaker Aakash Desai, Mayo Clinic, United States

Topic Poster Listing

Keywords

Mayo Clinic

Rochester

Minnesota

lurbinectedin

second-line treatment

extensive stage-small cell lung cancer

ES-SCLC

patients

real-world outcomes

study